China’s National Reimbursement Drug List (NRDL) 2020: What…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has…
Tagged with Pricing
China: New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s…
Navigating the Increasingly Stormy Waters of US Market Access
Certara's Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required…
EUnetHTA’s Uncertain Future & the Evolution of…
The journey of EUnetHTA began back in 2004, when the European Commission and Council of Minsters requested the establishment of a sustainable European…
5 Trends for Life Science Companies to Watch in 2021
After a transformative 2020, Shawview Consulting’s Brendan Shaw looks into his crystal ball and makes five predictions (plus one) on the key trends…
Niklas Hedberg – Chair of the Executive Board, EUnetHTA;…
Niklas Hedberg outlines the role of EUnetHTA as both a network and project built up of national HTAs in Europe, the potential for a continent-wide…
Cross Country Collaborations in Europe: The Future of Pricing…
Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland examines the trend of collaboration between European countries…
Novartis Oncology President: “If We Offer Pay-For-Performance,…
During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement…
Marcel Plattner – President, vips, Switzerland
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing…
Axel B Müller – Managing Director, Intergenerika,…
Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…
Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…
Has the Time Truly Come for Trudeau’s ‘National Pharmacare’…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the…
